28 June,2021 12:37 PM IST | New Delhi | PTI
Serum Institute of India chief executive officer Adar Poonawalla
Vaccine major Serum Institute of India chief executive officer Adar Poonawalla on Monday said he has taken up the issues faced by Indians who have taken the Covishield jab travelling to the European Union at highest levels and hoped to resolve them soon.
Covishield is the Oxford University-AstraZeneca vaccine manufactured in India by the Pune-based vaccine maker.
"I realise that a lot of Indians who have taken Covishield are facing issues with travel to the EU, I assure everyone, I have taken this up at the highest levels and hope to resolve this matter soon, both with regulators and at a diplomatic level with countries," Poonawalla said in a tweet.
ALSO READ
Bharat Biotech co-founder Dr. Krishna Ella awarded by Johns Hopkins
INSACOG data says 290 cases of Covid-19 variant KP.2, 34 cases of KP.1 detected
ICMR slams Covaxin study for poor methodology
2,100 cases of Covid sub-variant JN.1, its lineages detected in India: INSACOG
India reports 133 new COVID-19 cases, active tally at 1,389
As of now European Union (EU) recognises Vaxzevria (previously Covid-19 Vaccine AstraZeneca, Oxford).
The other vaccines approved by the European Medicine Agency are Comirnaty by BioNTech-Pfizer, Moderna and Janssen (Johnson & Johnson).
This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever.
